TTPH With no material news, the company has moved off the bottom and has shown remarkable stamina. Currently at $9/share, this was under $4/share after a nosedive of epic proportions when their last study failed to reach stat sig level for Eravacycline. Something tells me that the latest confirmation trial is going well.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.